ESMO 2022: Survival, Response Rate Superior With Oral Sotorasib Versus Docetaxel for NSCLC
Drug may be major advancement for NSCLC patients with KRAS G12C mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.